Literature DB >> 17899628

The leishmaniases--survival and expansion in a changing world. A mini-review.

Jeffrey Shaw1.   

Abstract

The number of cases of visceral and cutaneous leishmaniasis is increasing globally at an alarming rate irrespective of the region and the leishmaniases are amongst the top emergent diseases in spite of control measures. In the present review attention is drawn to some of the reasons for this. The leishmaniases have expanded beyond their natural ecotopes due to the ecological chaos caused by man and this in turn affects the levels of his exposure to the vectors. Examples of how different phenomana (such as war, civilian migration, immuno-suppression caused by medication and viral infections, globalization of work and leisure and transmission outside endemic areas) contribute to the spread and increase of the disease are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17899628     DOI: 10.1590/s0074-02762007000500001

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  32 in total

1.  EST sequencing of blood-fed and Leishmania-infected midgut of Lutzomyia longipalpis, the principal visceral leishmaniasis vector in the Americas.

Authors:  André N Pitaluga; Vicente Beteille; Amanda R Lobo; João R Ortigão-Farias; Alberto M R Dávila; Adelson A Souza; J Marcelo Ramalho-Ortigão; Yara M Traub-Cseko
Journal:  Mol Genet Genomics       Date:  2009-06-30       Impact factor: 3.291

2.  A series of case reports of autochthonous visceral leishmaniasis, mostly in non-endemic hilly areas of Nepal.

Authors:  Sher Bahadur Pun; Kishor Pandey; Rajesh Shah
Journal:  Am J Trop Med Hyg       Date:  2012-12-18       Impact factor: 2.345

3.  Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB/c mouse.

Authors:  Catherine S Nation; Blaise Dondji; Gabrielle A Stryker
Journal:  Parasitol Res       Date:  2012-04-04       Impact factor: 2.289

4.  Hemophagocytic Lymphohistiocytosis Associated with Visceral Leishmaniasis: Varied Presentation.

Authors:  Piyush Ranjan; Vivek Kumar; Shuvadeep Ganguly; M Sukumar; Sanchit Sharma; Neha Singh; Naval K Vikram; Hara Prasad Pati; Rita Sood
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-28       Impact factor: 0.900

5.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

6.  Epidemiological trend of cutaneous leishmaniasis in two endemic focus of disease, south of Iran.

Authors:  Moosa Khosravani; Zahra Nasiri; Davood Keshavarz; Azam Rafat-Panah
Journal:  J Parasit Dis       Date:  2016-01-14

7.  Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate.

Authors:  Eric T Larson; Jessica E Kim; Frank H Zucker; Angela Kelley; Natascha Mueller; Alberto J Napuli; Christophe L M J Verlinde; Erkang Fan; Frederick S Buckner; Wesley C Van Voorhis; Ethan A Merritt; Wim G J Hol
Journal:  Biochimie       Date:  2010-12-07       Impact factor: 4.079

8.  The biology and control of leishmaniasis vectors.

Authors:  David M Claborn
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.

Authors:  Noah Craft; Ron Birnbaum; Natalie Quanquin; Marie Crisel B Erfe; Cara Quant; Jacquelyn Haskell; Kevin W Bruhn
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

10.  N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis.

Authors:  James A Brannigan; Barbara A Smith; Zhiyong Yu; Andrzej M Brzozowski; Michael R Hodgkinson; Asher Maroof; Helen P Price; Franziska Meier; Robin J Leatherbarrow; Edward W Tate; Deborah F Smith; Anthony J Wilkinson
Journal:  J Mol Biol       Date:  2009-12-28       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.